Texas Warhound is going to clone the best working dogs, modify their genes and equip them with endoryl gear. The company raised $200 million in initial funding. The idea was developed by the head of giant biotechnological sciences, Ben Lam, and the founder of the Andoril weapons company, Palmer Lackey. But they themselves refuse the title of founders. Lucky doesn't own a stake, the technology is licensed to Colossal, and the business is run by former Pentagon data chief David Spark. Customers are drawn to a shortage of suitable animals. According to War Dog itself, more than 80% of service dogs in the US are purchased in Europe, and less than half of those purchased end up working full-time. It takes about 3 years to make. Therefore, for every 100 active dogs, the current pipeline requires more than 200 candidates. Lam said a biobank of successful dogs has already been created. Colossal contributes cell-editing technology, and its ViaGen company must clone the selected animals. Initially, they hope to eliminate inherited variants that cause muscle and other diseases. Improving the sense of smell remains a goal for now. The appearance of the puppies is planned for the beginning of 2027, delivery of ready dogs about two years later. War Dog has yet to donate a single batch of genetically enhanced service dogs. The idea already has a proven base outside of an American startup. Researchers from Seoul National University have cloned 7 puppies of an unusual drug-sniffing dog. In a study published in 2014, 86% of cloned animals were considered suitable, compared to 30% of conventionally bred dogs. This is the result of little experience and not a guaranteed factor for the US military. This experience indicates that genomic selection can increase the yield of suitable animals. The economics of the project remain to be tested. If the percentage of eligible dogs did rise from 50% to below 86%, approximately 117 applicants would be enough to produce 100 service animals.

Texas Warhound is going to clone the best working dogs, modify their genes and equip them with endoryl gear. The company raised $200 million in initial funding. The idea was developed by the head of giant biotechnological sciences, Ben Lam, and the founder of the Andoril weapons company, Palmer Lackey. But they themselves refuse the title of founders. Lucky doesn't own a stake, the technology is licensed to Colossal, and the business is run by former Pentagon data chief David Spark. Customers are drawn to a shortage of suitable animals. According to War Dog itself, more than 80% of service dogs in the US are purchased in Europe, and less than half of those purchased end up working full-time. It takes about 3 years to make. Therefore, for every 100 active dogs, the current pipeline requires more than 200 candidates. Lam said a biobank of successful dogs has already been created. Colossal contributes cell-editing technology, and its ViaGen company must clone the selected animals. Initially, they hope to eliminate inherited variants that cause muscle and other diseases. Improving the sense of smell remains a goal for now. The appearance of the puppies is planned for the beginning of 2027, delivery of ready dogs about two years later. War Dog has yet to donate a single batch of genetically enhanced service dogs. The idea already has a proven base outside of an American startup. Researchers from Seoul National University have cloned 7 puppies of an unusual drug-sniffing dog. In a study published in 2014, 86% of cloned animals were considered suitable, compared to 30% of conventionally bred dogs. This is the result of little experience and not a guaranteed factor for the US military. This experience indicates that genomic selection can increase the yield of suitable animals. The economics of the project remain to be tested. If the percentage of eligible dogs did rise from 50% to below 86%, approximately 117 applicants would be enough to produce 100 service animals.